



FOR IMMEDIATE RELEASE:

Hutchinson BioTech Loses Federal Funding  
Updated March 21, 2008

The United States Department of Defense recently announced a cut in expenditure for several projects being developed by Hutchinson BioTech. These cuts affect a number of projects for enhancing the war fighting capabilities of our American Soldiers.

The cuts, also, affect a few of the recently released commercial products distributed by Hutchinson BioTech. Most notable of these cuts was the decision to halt purchases of the sleep-control drug Clorica. Clorica was slated to be distributed to pilots and soldiers deployed for the war on global terrorism.

However, the HBT genetically engineered cotton designed to stimulate coagulation of blood has been approved for battlefield testing and will soon be available to our soldiers. The HBT cotton is woven into the soldiers' uniforms then activated and dispersed to wounds when the uniform is penetrated by debris or projectiles such as bullets and shrapnel.

The spokesperson for the Department of Defense noted that they wished to maintain a working relationship with Hutchinson and that the budget cuts were placed in response to the economic stimulus plan congress passed in January 2008. Representatives from Hutchinson declined to comment on the situation.

Concerned citizens should contact their state representatives to inform them of the displeasure that our American Soldiers will be losing the benefit of a number of Hutchinson BioTech projects which are being designed to enhance our their war fighting capabilities

From the desk of:

**Randy Slive**  
Senior Public Relations Manager  
Hutchinson BioTech